Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.

Martina MilaniEleonora MammarellaSimona RossiChiara MieleSerena LattanteMario SabatelliMauro CozzolinoNadia D'AmbrosiSavina Apolloni

Published in: Journal of neuroinflammation (2021)

Our findings show that S100A4 has a role in ALS-related mechanisms, and that drugs such as niclosamide which are able to target inflammatory and fibrotic pathways could represent promising pharmacological tools for ALS.

Keyphrases

amyotrophic lateral sclerosis
oxidative stress
systemic sclerosis
cancer therapy
idiopathic pulmonary fibrosis
drug delivery
drug induced